Seeking Alpha

AC Immune Showcasing Precision Medicine Programs at AAIC 2023

Lausanne, Switzerland, July 3, 2023 – AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations at ...
Seeking Alpha

Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases

Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup ...
Business Wire

Repertoire Immune Medicines to Provide Progress Updates on Clinical Programs and Discovery Platform at J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Repertoire Immune Medicines, a clinical-stage biotech company creating a new category of immune therapies for cancer, autoimmunity and infectious disease, today ...
Business Wire

Repertoire Immune Medicines Secures $189M Financing to Advance Pipeline Programs and Discovery Platform Directed at Cellular Immune Targets

- Company to further expand its DECODE™ discovery platform, accelerate multiple oncology clinical programs, and advance discovery programs in oncology, autoimmune disorders, infectious disease, and ...
Nasdaq

AC Immune to Highlight First-in-Class Alzheimer’s Disease Vaccine Programs at Upcoming Investor Conferences

LAUSANNE, Switzerland, May 20, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today ...
Yahoo Finance

Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases

CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that, following advancement of key startup ...